Earl Avramis

Fate Therapeutics (United States) — United States

Medicine · Health Sciences

14h-index1.5kcitations78works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(51), Immunotherapy and Immune Responses(22), Virus-based gene therapy research(21), Cancer Immunotherapy and Biomarkers(20), Immune Cell Function and Interaction(19)

Publications78 total

A novel CD3ε fusion receptor allows T cell engager use in TCR-less allogeneic CAR T cells to improve activity and prevent antigen escape
Molecular Therapy·2025· 1 citedOpen Access
308 A novel avidity-enhancing receptor (AvER) for superior CAR-dependent specificity and activity against tumor cells
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract 3995: A novel chimeric Fas signal redirect receptor enhances the durability of anti-tumor activity and serial killing potential of CAR T cells
Cancer Research·2024
Abstract 5240: Novel CD3-Fusion Receptor enables combination of T-cell engagers and allogeneic CAR T cells to promote enhanced antitumor activity and overcome antigen escape
Cancer Research·2024
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors
Med·2023· 22 citedOpen Access
Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
2023Open Access
Data from Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function
2023Open Access
Supplementary Table 1 from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Data from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
2023Open Access
Data from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Supplementary Figure 1 from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Supplementary Figure 4 from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Supplementary Figures 1 - 8 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
2023Open Access
Supplementary Figure Legends from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Supplementary Figure 1 from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Supplementary Figure 4 from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
Supplementary Table 1 from Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function
2023Open Access
Supplementary Table 1 from Exposure to a Histone Deacetylase Inhibitor Has Detrimental Effects on Human Lymphocyte Viability and Function
2023Open Access
Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
2023Open Access
Supplementary Figure 3 from PD-1 Blockade Expands Intratumoral Memory T Cells
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Antoni Ribas(41), Thinle Chodon(34), Bartosz Chmielowski(27), Begoña Comı́n-Anduix(26), Richard C. Koya(21), Paula Kaplan‐Lefko(20), Charles Ng(20), Elizabeth Seja(19), John A. Glaspy(19), Alistair J. Cochran(17), David Baltimore(17), James S. Economou(17), Zhongqi Wu(16), James R. Heath(16), Owen N. Witte(16), Mohammad Atefi(15), Deborah J. Wong(14), Begonya Comin-Anduix(14), Caius G. Radu(12), Martin Auerbach(11)